Westfield Capital Management
XENE icon

Westfield Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Westfield Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91M Buy
1,507,294
+105,811
+8% +$5.87M 0.3% 98
2026
Q1 		$81.5M Buy
1,401,483
+174,712
+14% +$8.05M 0.34% 94
2025
Q4 		$55M Buy
1,226,771
+20,705
+2% +$870K 0.23% 143
2025
Q3 		$48.4M Buy
1,206,066
+53,461
+5% +$1.88M 0.2% 151
2025
Q2 		$36.1M Sell
1,152,605
-238,765
-17% -$7.79M 0.15% 168
2025
Q1 		$46.7M Buy
1,391,370
+234,181
+20% +$8.89M 0.23% 138
2024
Q4 		$45.4M Buy
1,157,189
+487,589
+73% +$20.2M 0.2% 144
2024
Q3 		$26.4M Buy
669,600
+26,054
+4% +$1.05M 0.12% 174
2024
Q2 		$25.1M Buy
643,546
+296,195
+85% +$11.8M 0.12% 180
2024
Q1 		$15M Buy
347,351
+109,856
+46% +$5.05M 0.08% 188
2023
Q4 		$10.9M Buy
+237,495
New +$8.39M 0.06% 187

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Westfield Capital Management's XENE Position: Q2 2026 in Review

Westfield Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 7.5% in Q2 2026, buying an estimated $5.87M and bringing the position to 1,507,294 shares worth $91M. The position accounts for 0.3% of the portfolio, ranked #98.

Westfield Capital Management first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Westfield Capital Management held 1,507,294 shares of Xenon Pharmaceuticals worth $91M as of Q2 2026.
  • Westfield Capital Management bought 105,811 Xenon Pharmaceuticals shares in Q2 2026, an estimated $5.87M.
  • Xenon Pharmaceuticals made up 0.3% of Westfield Capital Management's portfolio in Q2 2026, its #98 holding.
  • Westfield Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Westfield Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.